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Background: Malignant germ cell tumours are the most common malignant tumours in young men. They are
histologically divided into seminomas and non-seminomas. Non-seminomas are further subdivided into embryonic
carcinomas, yolk sac tumours, chorionic carcinomas, and teratomas. For the therapeutic management it is essential
to differentiate between these histological subtypes.
Methods: Investigated cases included normal testis (n = 50), intratubular germ cell neoplasia (n = 25), seminomas
(n = 67), embryonic carcinomas (n = 56), yolk sac tumours (n = 29), chorionic carcinomas (n = 2), teratomas (n = 7)
and four metastases of YST’s for their CK19 expression. In addition Leydig cell- (n = 10) and Sertoli cell- tumours
(n = 4) were included in this study.
Results: All investigated seminomas, embryonic carcinomas as well as normal testis and intratubular germ cell
neoplasias did not express CK19. In contrast, all investigated yolk sac tumours strongly expressed CK19 protein.
These findings became also evident in mixed germ cell tumours consisting of embryonic carcinomas and yolk sac
tumours, although CK19-expression could also be observed in analysed chorionic carcinomas and epithelial
components of teratomas.
Conclusion: CK19 proved to be a sensitive marker to identify yolk sac tumours of the testis and to distinguish
them from other germ cell tumours, especially seminomas and embryonic carcinomas.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/4075546891400979.
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Testicular germ cell tumours (TGCTs) are the most
common malignancies in young men at the age of 15 to
40 years [1]. The incidence has constantly increased over
the last 40 years [2]. TGCTs are histologically and clinically
grouped into seminomas (SEM) and non-seminomas.
Non-seminomas are further subdivided into embryonic
carcinomas (EC), yolk sac tumours (YST), chorionic car-
cinomas (CC), and teratomas (TER) [3].
The distinction between the different histological tumour
types is important for the therapeutic management. Several
immunohistochemical markers have been established to* Correspondence: felix.bremmer@med.uni-goettingen.de
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unless otherwise stated.differentiate these tumour types. Intratubular germ cell
neoplasia unclassified (IGCNU) and seminomas show an
expression of D2-40, CD117, OCT3/4, and SALL4 in most
of cases [4-7]. Embryonic carcinomas express OCT3/4,
NANOG, CD30, Sox-2, and cytokeratin [4,8,9]. YST ex-
press cytokeratin, glypican-3, and alpha-feto protein (AFP),
albeit the latter, being represented in only about 50% of all
cases [10,11]. In addition to their expression in YST, AFP
and Glypican-3 are expressed in hepatic tumours [12,13].
In the context of AFP and Glypican-3 CK19 is used as a
cell marker of the hepatic biliary tract [14] and its progeni-
tor cells [15].
In addition to intrahepatic cholangiocarcinoma [16] and
hepatocellular carcinoma [17] several other tumours have
been shown to express CK19, including papillary thyroid
carcinoma [18], breast cancer [19], lung cancer [20].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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YST are rare. In this study we will introduce CK19 as a
new relevant marker for YST within the group of TGCT.
Methods
Tissue samples of primary TGCT
Tumour tissues from orchiectomy specimens were ac-
quired from the University Medical Centre Göttingen and
RWTH Aachen, Germany. Tumours were classified and
staged on the basis of the WHO classification [21]. The in-
vestigated cases included tumour-free testis (n = 50) and
IGCNU (n = 25) from patients with TGCT’s. Tumour sam-
ples implied pure seminomas (n = 57), pure embryonic car-
cinomas (n = 20), pure YST (n = 2), pure CC (n = 1) and
mixed germ cell tumours (n = 38) consisting of SEM+ EC
(n = 10), EC+YST (n = 18), EC+YST+TER (n = 7), SEM+
YST (n = 2) and EC +CC (n = 1). Furthermore, four metas-
tases of YST in the omentum majus (n = 1), lung (n = 1)
and lymph nodes (n = 2) have been investigated. In addition
14 tumours of the sex cord/stroma group were also investi-
gated, in particular Leydig cell tumours (n = 10) and Sertoli
cell tumours (n = 4). All specimens were immediately fixed
in formalin and embedded in paraffin. Ethical approval for
using human material in the present study was obtained
from the ethics committee of the University Medical Centre
Göttingen and RWTH Aachen. Two independent investi-
gators evaluated all tissue sections.
Immunohistochemistry
Immunohistochemical reactions were performed on 4-μm
formalin-fixed and paraffin-embedded tissue sections. Sec-
tions were stained on a Dako Autostainer with the Dako
EnVision™ FLEX+ detection system (Dako, Glostrup,
Denmark). The system detects primary mouse and rabbit
antibodies and the reaction is visualised by EnVision™
FLEX DAB+ Chromogen. Using EnVision™ FLEX+ Mouse
(LINKER) or EnVision™ FLEX+ Rabbit (LINKER) (Code
K8019) signal amplification of primary mouse antibodies
or primary rabbit antibodies were presented, respectively.
The deparaffinization, rehydration, and heat-induced
epitope-retrieval (HIER) were carried out in one step with
the 3-in-1 procedure buffer (Dako Target Retrieval Solu-
tion), pH 9 high ((10x)(3-in-1) Code S2375)) or pH 6 low,
[(10x)(3-in-1) Code S1699)] at 97°C using a PT Link, Pre-
Treatment Module (Dako). Tissue samples were analysed
by light microscopy after 8 minutes counterstaining with
Meyer’s haematoxylin (Dako). As primary antibodies we
used Anti-CK19, −Glypican-3 and -AFP (Table 1).
Results
CK19 expression in normal testis, IGCNU, seminoma, and
embryonic carcinoma
Normal testis, cells of the interstitium and Leydig cells
did not express CK19 (Figure 1A), Glypican-3, or AFP.In addition IGCNU (Figure 1B), all examined semino-
mas (Figure 1C) and embryonic carcinomas (Figure 1D)
did not express CK19, Glypican-3, or AFP. In all exam-
ined tissues the rete testis and the epidymides showed a
strong cytoplasmatic and membrane bound expression
of CK19 protein (Figure 1 A-D).
CK19 expression in YST, teratomas, and chorionic
carcinomas
All 29 YST strongly expressed Glypican-3 and CK19. The
immunohistochemical signals were located within the cyto-
plasma and at the cell membrane (Figure 1 E-G). In con-
trast, only 18 of these tumours showed a patchy expression
of AFP (Figure 1H). CK19 expression was evident in the dif-
ferent growth patterns of YST such as reticular/microcystic
pattern (Figure 2A and B), solid pattern (Figure 2C and D),
papillary pattern (Figure 2E and F) or endodermal sinus pat-
tern with festooned appearance (Figure 2G and H). The
CK19 positivity could also be shown in tumours consisting
of YST and embryonic carcinomas (Figure 3A and B)
as well as in metastasis of the omentum majus (Figure 3C
and D), lung (Figure 3E and F) and lymph nodes (data not
shown).
Teratomas, in line with their histologic heterogeneity,
showed a great diversity of CK19 expression, which was
mainly confined to the different epithelial structures,
whereas mesodermal derivatives did not show CK19 expres-
sion (Figure 3G and H). Both investigated chorionic carcin-
omas showed a strong CK19 expression (data not shown).
CK19 expression in sex cord/gonadal stroma tumours
The ten Leydig cell tumours and four Sertoli cell tu-
mours of the testis did not express CK19. Table 2 shows
the expression pattern of all investigated proteins inves-
tigated in this study (Table 2).
Discussion
YST are rare malignant germ cell tumour of the testis.
They occur in about 44% of cases in adults as a component
of a mixed tumour, whereas pure YST are rare at this age
[21,22]. Pure YST are the second most common malignant
germ cell tumours of infancy [23,24]. YST show many dif-
ferent growth patterns such as the reticular/microcystic,
macrocystic, solid, hepatoid, enteric, glandular/alveolar,
papillary, endodermal-sinus-like or myxomatous poly-
vesikular [25] subtype. Although the distinction of
these (several) growth patterns is not essential for
therapy, the vast morphological diversity complicates
the diagnosis of YST. In this study we looked for a new
sensitive marker, which can be used for the differential
diagnosis of YST.
The keratin family constitutes the intermediate fila-
ment proteins responsible for the structural integrity of
epithelial cells and is subdivided into cytokeratins and
Table 1 Antibodies used in this study
Antibody Clonality Buffer Dilution Incubation
Anti-CK19 monoclonal mouse high Ready to use 20 min (IR 615 Dako)
Anti-AFP polyclonal rabbit high Ready to use 30 min (IR 6500 Dako)
Anti-Glypican-3 monoclonal mouse low Ready to use 30 min (G1829R06 DCS Immunoline)
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[26]. CK19 expression has been detected in several types
of human cancers, including papillary thyroid carcin-
oma, breast cancer, lung cancer, intrahepatic cholangio-







Figure 1 CK19-expression in normal testis and germ cell tumours of the
seminoma (C, x100), and embryonic carcinoma (D, x100). In all cases the rete te
CK19 (A-D). YST of the testis with microcystic pattern (E, HE staining x200) expAll 29 examined YST showed strong CK19 expression.
This expression was also found in mixed germ cell tu-
mours consisting of more than one histological type and
could be used to distinguish YST from other germ cell








testis. CK19 is not expressed in normal testis (A, x40), IGCNU (B, x40),
stis showed a strong cytoplasmic and membrane bound expression of












Figure 2 CK19-expression in different growth pattern of yolk sac tumours. CK19 shows a strong cytoplasmic and membrane bound
expression in YST with microcystic- (A, HE staining x200 and B, immunostaining, x200), solid- (C, HE staining x100+ D, immunostaining, x100),
papillary- (E, HE staining x100 and F, immunostaining, x100) and endodermal sinus- rowth pattern (G, HE staining x40 and H, immunostaining, x40).
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cinomas [27]. In our study, however, CK19 expression
could not be detected in a total number of 56 embryonic
carcinomas. This became particularly evident in mixed
tumours consisting of YST and embryonic carcinomas.
Furthermore, CK19 expression was also confirmed in me-
tastases of an YST in the omentum majus, lung, lymph
nodes, and in a primary YST of the ovary. Glypican-3 as an
established marker for YST could also be observed in all
analysed cases of YST, whereas AFP showed an expression
in only 18 out of 29 cases.We found CK19 expression in the two analysed
chorionic carcinomas as described also by Clark et al.
[28]. All other analysed cases of malignant and non-
malignant tumours of the testis did not show CK19
expression. Because glypican-3 can be also expressed
in chorionic carcinoma, this tumour has to be ex-
cluded by morphological criteria and expression of β-HCG
[10,11].
For the diagnosis of YST several markers such as Kera-
tin, Glypican-3 or in some cases AFP can be used. CK19













Figure 3 CK19-expression in mixed germ cell tumours of the testis and metastases. YST showing a strong expression of CK19 and
embryonic carcinoma component in the same tumour does not express CK19 protein (A and B, x100). Omentum majus with metastasis of an
YST (C, HE staining x40) expressing CK19 protein (D, x40). Pulmonary metastases of an YST of the testis (E, HE staining x40) express CK19 (F, x40).
Intestinal mucosa in teratomas (G, x40+ H, x100) shows positive CK19-expression.
Table 2 Expression pattern of CK19, Glypican-3 (GLP-3), and AFP in testicular tumours
TF(n = 50) IGCNU(n = 25) SEM(n = 67) EC(n = 56) YST(n = 29) CC(n = 2) LCT(n = 10) SCT(n = 4)
CK19 0/50 0/25 0/67 0/56 29/29 2/2 0/10 0/4
GLP-3 0/50 0/25 0/67 0/56 29/29 0/2 0/10 0/4
AFP 0/50 0/25 0/67 0/56 18/29 0/2 n.d n.d
(TF = normal testis, IGCNU = intratubular germ cell neoplasia, SEM = seminoma, EC = embryonic carcinoma, YST = yolk sac tumour, TER = teratoma, CC = chorionic
carcinoma, LCT = leydig cell tumours, SCT = sertoli cell tumours).
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especially Glypican-3.
It has been shown previously that cells of hepatocellular
carcinomas expressing e.g. CK19 may result from dediffer-
entiation of hepatocytes into a progenitor cell/biliary
phenotype [29,30]. According to the diagnostic role of
CK19 in yolk sack tumours as we described in this study,
CK19 expression might be a clue for differentiation to a
hepatocyte or biliary phenotype in this tumour entity. This
would be in line with the known expression of glypican-3
or AFP in these tumours.
CK19 is widely applied as a post-operative diagnostic
marker of papillary thyroid carcinoma. It is mandatory
to elucidate further whether this holds true also for YST.
Conclusion
CK19 proved to be a sensitive marker for the diagnosis of a
primary YST of the testis and metastases. Its expression
can be used to differentiate YST of the testis from other
germ cell tumours and sex cord/gonadal stroma tumours.
In addition, CK19 may be a possible and helpful pre/post-
operative serum marker of YST.
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